您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 抗癌药物->治疗肠癌药物
处方药:处方药
包装规格: 300毫克/15毫升/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
辉瑞制药
生产厂家英文名:
PFIZER INC
该药品相关信息网址1:
http://www.drugs.com/camptosar.html
该药品相关信息网址2:
http://www.pfizer.com/products/rx/rx_product_camptosar.jsp
原产地英文商品名:
CAMPTOSAR 300mg/15ml/Vial
原产地英文药品名:
IRINOTECAN HCL
中文参考商品译名:
坎普土沙 300毫克/15毫升/瓶
中文参考药品译名:
盐酸伊立替康
原产地国家批准上市年份:
1996/06/14
英文适应病症1:
rectum metastatic ca
英文适应病症2:
colon metastatic car
英文适应病症3:
carcinoma
英文适应病症4:
cancer
临床试验期:
完成
中文适应病症参考翻译1:
直肠转移癌
中文适应病症参考翻译2:
结肠转移癌
中文适应病症参考翻译3:
肠癌
中文适应病症参考翻译4:
癌症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20107519202712.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文CAMPTOSAR信息资料(仅供参考)

【药物功效】:适用于治疗成人转移性大肠癌,也可用于其它肿瘤(如胃癌、胰腺癌、宫颈癌、卵巢上皮细胞癌等)。
禁忌症(1)肝肾功能不全者或血胆红素超过正常值上限1.5倍的患者。(2)有慢性肠炎和(或)肠梗阻的患者。(3)对本药有严重过敏史者。(4)严重骨髓抑制者。(5)WHO行为状态评分(BaselinePerformance)大于2的患者。(6)孕妇。(7)哺乳期妇女。
【注意事项】:
1慎用WHO行为状态评分为2的患者。
2药物对老人的影响由于老年人各项生理功能(尤其是肝功能)可能有所减退,故老年患者用药时须谨慎。
3药物对妊娠的影响在兔和大鼠实验中,发现本药对胎仔有毒性、致畸性。因此,妇女于妊娠期间不能使用本药,育龄妇女在接受本药治疗期间应避孕(直至治疗结束后3个月)。美国药品和食品管理局(FDA)对本药的妊娠安全性分级为D级。
4药物对哺乳的影响在哺乳大鼠的乳汁中发现了☆14☆C标记的本药,但目前尚无法证实本药是否会经人乳分泌。由于本药可能对母乳喂养儿有毒性,故在使用本药治疗期间应停止母乳喂养。
5用药前后及用药时应当检查或监测在每个治疗周期前均应检查肝功能,治疗期间应每周检查全血细胞计数。
【不良反应】:
1.血液系统可见中性粒细胞减少、贫血、嗜酸粒细胞增多和血小板减少。(1)中性粒细胞减少是本药的剂量限制性毒性,但具有可逆性和非蓄积性,中性粒细胞到最低值的中位时间为8天,通常在第22天完全恢复正常。78.7%的患者出现过中性粒细胞减少,严重者(中性粒细胞计数低于0.5×10☆9☆/L)占22.6%。6.2%的患者(按周期为1.7%)出现严重中性粒细胞减少合并发热。10.3%的患者(按周期为2.5%)出现感染;5.3%的患者(按周期为1.1%)出现严重中性粒细胞减少性感染,其中有2例患者死亡。"每周治疗方案"及"3周治疗方案"引起的3-4级中性粒细胞减少分别为14%、22%,曾接受过盆腔/腹部放疗者与未接受者3-4级中性粒细胞减少分别为48%、24%。(2)贫血的发生率为58.7%。有报道,3-4级贫血发生率为7%,10%患者需要输血。(3)有1/3患者可见嗜酸粒细胞增多。(4)有7.4%的患者(按周期为1.8%)出现血小板减少(低于100×10☆9☆/L),几乎均在第22天得到恢复,接受"3周治疗方案"者血小板减少发生率为1%-4%。
2.心血管系统曾报道有心律失常、心肌缺血、心功能异常。
3.中枢神经系统可有眩晕、失眠。报道有1例患者出现构音障碍。
4.胃肠道腹泻也是本药剂量限制性毒性,在所有听从腹泻处理措施忠告的患者中有20%发生严重腹泻。出现第一次稀便的中位时间为滴注本药后第5日。常见的还有腹部痉挛性疼痛、恶心、呕吐、畏食、粘膜炎,其中3-4级恶心及呕吐的发生率约为20%。有不到10%的患者出现便秘。据报道还可有麻痹性肠梗阻、假膜性结肠炎。
5.泌尿生殖系统有7.3%的患者出现短暂的轻至中度血清肌酸酐升高。偶有患者发生肾衰竭,可能与腹泻引起的肾脏低灌注有关。
6.肝可出现氨基转移酶、碱性磷酸酶、胆红素水平轻至中度短暂升高,其发生率分别为9.2%、8.1%和1.8%(指在无进展性肝转移的患者)。有报道,3-4级氨基转移酶升高仅发生于已有肿瘤肝转移的患者。
7.呼吸系统可有呼吸困难和咳嗽,3-4级呼吸道症状发生率为4%-10%。尚报道有肺炎。
8.皮肤较常见多汗、皮肤潮红、皮肤温暖感,少见皮疹、静脉滴注部位疼痛。脱发的发生率为12%-70%。
9.骨骼肌肉系统"每周治疗方案"者肌无力发生率为76%。接受"每周治疗方案"或"3周治疗方案"的患者3-4级肌无力发生率为12%-15%。还有全身性虚弱和疲乏的报道。
10.胆碱能综合征有9%的患者出现短暂严重的急性胆碱能综合征。主要表现为早发性腹泻以及其它征象,如腹痛、结膜炎、鼻炎、低血压、血管舒张、出汗、寒战、全身不适、头晕、视力障碍、瞳孔缩小、流泪、流涎增多,以上症状多与用药后第一个24小时内发生,使用阿托品治疗后消失。
【给药说明】:
1.本药配伍禁忌尚不清楚,但建议不要与其它药物混合。
2.本药应静脉滴注给药,不能静脉注射。静脉滴注时间一般为30-90分钟。
3.使用本药后24小时内,有可能出现头晕及视力障碍,因此用药后禁止驾车。
4.在配制本药时应戴眼镜、口罩、手套等。如皮肤接触药液,立即用肥皂和清水彻底冲洗。如粘膜接触药液,立即用清水冲洗。
5.所有用于稀释或输液的材料均需按照细胞毒性药物的标准处理程序进行处置。
6.本药溶液首次打开后在室温下可保存12小时,在2-8℃下可保存24小时,但稀释后应立即使用。
7.迟发性腹泻的处理:因腹泻治疗不当可能危及生命,患者用药后,一旦出现第一次稀便,需饮用大量含电解质的液体,并立即给予适当的抗腹泻治疗。当出现以下情况时,患者应住院治疗腹泻:(1)腹泻同时伴有发热。(2)严重腹泻。(3)已用大剂量洛哌丁胺治疗,但48小时后仍有腹泻。建议出院患者携带一定数量的抗腹泻药。
8.可用昂丹司琼和苯海拉明预防本药所致的胃肠道反应。为预防或减弱早期腹泻(使用本药后不久即出现的腹泻)和其它胆碱能症状,可在用药前静脉或皮下注射阿托品0.25-1mg。晚期腹泻(迟发性腹泻,通常使用本药24小时后)可给予洛哌丁胺治疗,在首次出现稀便或肠蠕动较正常频繁时给药:首次给予4mg,以后每2小时给予2mg,直至腹泻停止后至少12小时;夜间可每4小时给予4mg。不应预防性使用洛哌丁胺(即使是上一周期已出现过迟发性腹泻者)。
9.使用本药期间,应避免使用具有通便作用的药物,因为可能会加重腹泻。出现严重腹泻的患者,在下一周期用药时应减量。
10.中性粒细胞减少性发热(体温超过38℃,中性粒细胞计数低于1×10☆9☆/L)应立即住院静脉滴注广谱抗生素治疗。只有当中性粒细胞计数高于1.5×10☆9☆/L时,方可恢复本药治疗。
11.当出现急性胆碱能综合征时,如没有禁忌,可使用硫酸阿托品治疗(0.25mg皮下注射)治疗。以后使用本药时,应预防性给予硫酸阿托品。
12.如患者出现了严重中性粒细胞减少或严重胃肠道不良反应,必须推迟使用本药,直到这些症状(尤其是腹泻)完全消失为止。
13.目前尚无关于药物过量的报道。在Ⅰ期研究中,在严密观察下使用剂量曾高达750mg/m☆2☆,最显著的不良反应是严重中性粒细胞减少和腹泻。目前尚无本药的特效解毒剂。
【用法用量】:
成人
·常规剂量
·静脉滴注应根据中性粒细胞计数调整剂量。推荐剂量为一次350mg/m☆2☆,每3周1次,持续使用直至病情加重或出现了严重毒性。对于无症状的严重中性粒细胞减少(低于0.5×10☆9☆/L)、中性粒细胞减少伴发热或感染(体温超过38℃、中性粒细胞计数低于或等于1×10☆9☆/L)或严重腹泻(需静脉输液治疗)的患者,下周期治疗剂量应减至300mg/m☆2☆,如仍出现以上不良反应,下一周期剂量可进一步减至250mg/m☆2☆。
[国外用法用量参考]
成人
·常规剂量
·静脉滴注
1.胃癌、胰癌、宫颈癌:一次100-150mg/m☆2☆,每1-2周1次。
2.卵巢上皮细胞癌:一次200mg/m☆2☆,每3-4周1次。
3.结肠直肠癌:
(1)单药治疗:①"每周治疗方案",对氟尿嘧啶治疗失败的患者,推荐本药初始剂量为一周125mg/m☆2☆,静脉滴注90分钟,使用4周后,停2周后可重复疗程,并根据毒性反应调整剂量。②"3周治疗方案",推荐初始剂量为每3周给药350mg/m☆2☆,静脉滴注90分钟。如果用药有效且未出现不可耐受的毒性,可长期坚持治疗。70岁或70岁以上者和(或)曾接受了骨盆或腹部放疗的患者,初始剂量为300mg/m☆2☆。必要时根据毒性反应调整剂量。
(2)联合用药:①甲酰四氢叶酸/氟尿嘧啶弹丸式注射方案:本药125mg/m☆2☆静脉滴注90分钟,之后立即先后静脉弹丸式注射甲酰四氢叶酸20mg/m☆2☆、氟尿嘧啶500mg/m☆2☆。以上药物均在每个疗程的第1、8、15、22日给予。下一疗程在第7周(第43日)开始。②甲酰四氢叶酸/氟尿嘧啶静脉滴注方案:在第1、15、29日给予本药180mg/m☆2☆,静脉滴注90分钟;在第1、2、15、16、29、30日静脉给予甲酰四氢叶酸200mg/m☆2☆,给药时间不应低于2小时;在给予甲酰四氢叶酸后立即静脉快速弹丸式注入氟尿嘧啶400mg/m☆2☆,然后静脉滴注氟尿嘧啶600mg/m☆2☆,滴注时间不应低于22小时。下一疗程在第7周(第43日)开始。
4.非小细胞肺癌:与顺铂联用(80mg/m☆2☆,在每个疗程的第1日给药),本药初始剂量为30mg/m☆2☆,在第1、8、15日给予,每28日重复1次。以后按10mg/m☆2☆递增(直至出现严重毒性)。最大耐受剂量可达70mg/m☆2☆。
·肝功能不全时剂量
有肿瘤肝转移但肝功能尚正常的患者不必调整剂量。对肝功能不全者,目前尚无具体推荐剂量。
【贮法】:密封,遮光保存。
【禁忌】:
(1)肝肾功能不全者或血胆红素超过正常值上限1.5倍的患者。
(2)有慢性肠炎和(或)肠梗阻的患者。
(3)对本药有严重过敏史者。
(4)严重骨髓抑制者。
(5)WHO行为状态评分(BaselinePerformance)大于2的患者。
(6)孕妇。
(7)哺乳期妇女。


Camptosar
Generic Name: irinotecan (EYE ri noe TEE kan)
Brand Names: Camptosar

What is Camptosar?
Camptosar (irinotecan) is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.

Camptosar is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.

Camptosar may also be used for other purposes not listed in this medication guide.

-------------------------------------------------------------------

Important information about Camptosar
Do not use Camptosar without telling your doctor if you are pregnant. It could cause harm to the unborn baby. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment. Camptosar can cause severe diarrhea, which can be life-threatening if it leads to dehydration. Diarrhea can occur soon after your injection or more than 24 hours later.

Your doctor may recommend you have an anti-diarrhea medicine such as loperamide (Imodium) available at all times while you are receiving Camptosar. Take the anti-diarrhea medication at the first sign of loose or frequent bowel movements.

Call your doctor if you still have diarrhea after 24 hours of taking anti-diarrhea medicine.

Avoid being near people who have colds, the flu, or other contagious illnesses. Contact your doctor at once if you develop signs of infection.

Do not receive a "live" vaccine while you are being treated with Camptosar, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you.

-------------------------------------------------------------------

Before receiving Camptosar
Do not receive Camptosar if you are allergic to irinotecan.

If you have any of these other conditions, you may need a dose adjustment or special tests to safely receive Camptosar:
liver disease;
an intestinal disorder or obstruction;
Gilbert's syndrome;
diabetes;
fructose intolerance (Camptosar contains sorbitol); or
if you are receiving radiation treatment to your abdomen or pelvic area.

FDA pregnancy category D. Camptosar can cause harm to an unborn baby. Do not receive this medicine without telling your doctor if you are pregnant. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment. It is not known whether irinotecan passes into breast milk or if it could harm a nursing baby. Do not receive Camptosar without telling your doctor if you are breast-feeding a baby.

-------------------------------------------------------------------

How is Camptosar given?
Camptosar is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting. The medicine must be given slowly through an IV infusion, and can take up to 90 minutes to complete. The Camptosar injection is usually followed by infusions with other cancer medications. These combination chemotherapy treatments are usually given at weekly intervals for several weeks.

Before starting your Camptosar injection, you may be given medications to help prevent nausea, vomiting, diarrhea, and other side effects. You may also need to use some of these medications for at least a day after receiving your injection.

Camptosar can cause severe diarrhea, which can be life-threatening if it leads to dehydration. Diarrhea can occur soon after your injection or more than 24 hours later.

Your doctor may recommend you have an anti-diarrhea medicine such as loperamide (Imodium) available at all times while you are receiving Camptosar. Take the anti-diarrhea medication at the first sign of loose or frequent bowel movements.

Call your doctor if you still have diarrhea after 24 hours of taking anti-diarrhea medicine. Do not take loperamide for longer than 2 full days without your doctor's advice.

To be sure Camptosar is not causing harmful effects, your blood will need to be tested on a regular basis. Your kidney or liver function may also need to be tested. Do not miss any scheduled visits to your doctor.

-------------------------------------------------------------------

What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment to receive your Camptosar injection.

-------------------------------------------------------------------

What happens if I overdose?
Seek emergency medical attention if you think you have received too much of this medicine.
Overdose symptoms may include fever, chills, body aches, flu symptoms, and severe diarrhea.

-------------------------------------------------------------------

What should I avoid while using Camptosar?
Do not use a laxative or stool softener during treatment with Camptosar. These products can worsen diarrhea that may be caused by this medicine.

Avoid being near people who have colds, the flu, or other contagious illnesses. Contact your doctor at once if you develop signs of infection.

Do not receive a "live" vaccine while you are being treated with Camptosar, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you.

Avoid getting this medicine on your skin. If this happens, wash the area thoroughly with soap and warm water.

Camptosar can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

-------------------------------------------------------------------

Camptosar side effects
Get emergency medical help if you have any of these signs of an allergic reaction to Camptosar: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
pale skin, easy bruising or bleeding, unusual weakness;
loose stools, watery diarrhea;
bloody or black stools;
runny nose, watery eyes, increased sweating, stomach cramps, and warmth, tingling, or redness under your skin;
fever, chills, body aches, flu symptoms;
white patches or sores inside your mouth or on your lips;
sudden numbness or weakness, headache, confusion, problems with vision, speech, or balance;
chest pain, pain or swelling in one or both legs;
swelling or irritation where the IV needle is placed;
nausea or vomiting that keeps you from drinking enough fluids; or
signs of dehydration, such as dry mouth, increased thirst, drowsiness, feeling light-headed, or fainting.

Less serious Camptosar side effects may include:
loss of appetite, constipation;
dizziness;
redness or peeling of the skin on your hands and feet;
cough,
temporary hair loss.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

-------------------------------------------------------------------

What other drugs will affect Camptosar?
Before receiving Camptosar, tell your doctor if you are using any of the following drugs:
a diuretic (water pill);
atazanavir (Reyataz);
ketoconazole (Nizoral);
rifabutin (Mycobutin);
rifampin (Rifadin, Rifater, Rifamate, Rimactane);
St. John's wort; or
seizure medicine such as carbamazepine (Carbatrol, Tegretol), phenobarbital (Luminal, Solfoton), or phenytoin (Dilantin).

This list is not complete and there may be other drugs that can interact with Camptosar. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

-------------------------------------------------------------------

Where can I get more information?
Your doctor or pharmacist can provide more information about Camptosar.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20107519202712.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

2011年4月25日更新

更新日期: 2015-01-12
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com